Leaning Tower YMCA site being razed, creation of a downtown Niles planned for the site: ‘We're in a renaissance'
'We're looking at the possibility of the area being surrounded by storefronts, apartments or condominiums, and creating an indoor/outdoor theater,' mayor George Alpogianis told Pioneer Press.
He said one interested party suggested building a theater with a retractable rear wall, similar to the roofs on many sports stadiums.
Also planned is creation of a pedestrian-friendly plaza anchored by the Leaning Tower of Niles, the 90-year-old half-scale replica of the Leaning Tower of Pisa in Italy.
On April 28, Alpogianis drove an excavator on the site of the former Niles Leaning Tower YMCA, at 6300 Touhy Ave., ceremoniously starting the work of tearing down the building – which was built in the 1960s adjacent to the village's landmark Leaning Tower of Niles, a half-scale replica of Italy's Leaning Tower of Pisa.
The landmark Leaning Tower remains standing, but the YMCA, which was shuttered by the YMCA of Metropolitan Chicago in May 2020 due to the COVID-19 pandemic, is costing the village $1.1 million to demolish, village spokesman Mitch Johnson told Pioneer Press in an email.
The demolition by contractor Ground Crew Demolition and Excavation is expected to take three months.
Last November, the Village Board authorized razing the building, eight months after purchasing the 6.6-acre YMCA property for $2.1 million, Johnson explained. This site is on the south end of the total 8 acres of land the village purchased in April 2019.
'We bought that with the mindset that Niles doesn't have a downtown, geographically it's impossible,' Alpogianis said. 'We decided Golf Mill will be our shopping district, and we looked at the south end of the village and we deemed that another district. That could be our downtown and Golf Mill could be uptown.'
Golf Mill Shopping Center, at the busy corner of Golf Road and Milwaukee Avenue, is scheduled for a $443 million facelift, the mayor explained. Developers are planning to begin demolition in late September in preparation of a three-year project expected to transform the 64-year-old mall.
Alpogianis said multiple entities had looked at the former Leaning Tower YMCA to repurpose it into some type of residential building or hotel. But the amount of money necessary to update the dated infrastructure was cost prohibitive. Village leaders decided it would be more financially feasible to start from new construction, and they began discussing what could be developed on that site – which is set in a tax increment financing district.
The YMCA site included two buildings, one that had residential units and other that included an activity center. The parcel was considered by village officials to be blighted and a town eyesore. The mayor was candid in his assessment of the site when officials announced in April 2024 that the village purchased it.
Alpogianis previously said the Leaning Tower YMCA site was '[expletive] disgusting. It is in shambles inside: It has been vandalized multiple times and there are multiple broken windows. People have been in there urinating, feces. I'm gonna assume there are rodents in there.'
Now, the mayor said he is in talks with multiple music promoters and some in the entertainment industry about a live performance theater — which could be part of the redevelopment — that could seat 3,000 to 6,000 people.
'There's been an outcry from our citizens dying to get a theater in Niles,' he said, adding that it would not only be a concert venue, but a live theater for plays and a community theater for local school graduations.
In addition to the theater and multi-use retail and residential that village leaders hope will be developed on the site, Alpogianis said they would like to create a grassy knoll, and in partnership with the Niles Park District, host public art and community events.
However, nothing has been formally submitted or reviewed by the Village Board for the site.
'We're in a renaissance in Niles right now,' Alpogianis said. 'Nothing of significance has been done for 25 years. … We all got together and pow-wowed. It's happening and all coming to fruition.'
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
The Hill
31 minutes ago
- The Hill
Target's COO will lead the struggling retailer when CEO Brian Cornell steps down in February
NEW YORK (AP) — Target CEO Brian Cornell, who helped reenergize the company but has struggled to turn around weak sales in a more competitive retail landscape since the COVID pandemic, plans to step down Feb. 1. Minneapolis-based Target Corp. said Wednesday that Chief Operating Officer Michael Fiddelke, a 20-year company veteran, will succeed Cornell. Cornell will transition to be executive chair of the board. Cornell, 66, took the helm at Target in August 2014. In September 2022, the board extended his contract for three more years and eliminated a policy requiring its chief executives to retire at age 65. Cornell said the appointment followed several years of board vetting of both internal and external candidates. Fiddelke has overhauled Target's supply network and expanded the company's stores and digital services while cutting costs. 'Mike was the right candidate to lead our business back to growth,' Cornell told reporters. 'As I arrived at Target, I consistently relied on Michael's strategic insights and sound judgment when making decisions. Michael has developed a deeper knowledge of our business than anyone I know.' Fiddelke told reporters he's stepping into the role with 'urgency' to reclaim the company's merchandising authority. 'When we're leading with swagger in our merchandising authority, when we have swagger in our marketing, and we're setting the trend for retail, those are some of the moments I think that Target has been at its highest in my 20 years,' he said. In May, Target announced that Fiddelke would lead a new office focused on faster decision-making to help accelerate sales growth. The change in leadership was announced Wednesday at the same time that Target reported another quarter of sluggish results. The company's stock was down more than 8% in pre-market trading. Target reported a 21% drop in net income in the quarter ended Aug. 2. Sales were down slightly and the company reported a 1.9% dip in comparable sales — those from established physical stores and online channels. Target has seen flat or declining comparable sales in eight out of the past 10 quarters including the latest period. Target, which has about 1,980 U.S. stores, has been the focus of consumer boycotts since late January, when it joined rival Walmart and a number of other prominent American brands in scaling back corporate diversity, equity and inclusion initiatives. Target's sales also have languished as customers defect to Walmart and off-price department store chains like TJ Maxx in search of lower prices. But many analysts think Target is stumbling because consumers no longer consider it the place to go for affordable but stylish products, a niche that long ago earned the retailer the jokingly posh nickname 'Tarzhay.' In fact, out of 35 merchandise categories that Target tracks, it gained or maintaining market share in only 14 during the latest quarter, Fiddelke told reporters Tuesday. Meanwhile, Walmart gained market share among households with incomes over $100,000 as U.S. inflation caused consumer prices to rise rapidly. Lower-income shoppers have driven customer growth at Target, suggesting it may have lost appeal with wealthier customers, according to market research firm Consumer Edge. 'It's probably not the best sign, especially because higher-income consumers continue to hold up a little bit better' during times of economic uncertainty, said Consumer Edge Head of Insights Michael Gunther. In March, members of Target's executive team told investors they planned to regain the chain's reputation for selling stylish goods at budget prices by expanding Target's lineup of store label brands and shortening the time it took to get new items from the idea stage to store shelves. The moves would help the company stay close to trends, executives said. 'In a world where we operate today, our guests are looking for Tarzhay,' Cornell told investors. 'Consumers coined that term decades ago to define how we elevate the everything everyday to something special, how we had unexpected fun in the shopping that would be otherwise routine.' Before joining Target, Cornell spent more than 30 years in leadership positions at retail and consumer-product companies, including as chief marketing officer at Safeway Inc. and CEO at Michaels, Walmart's Sam's Club and PepsiCo America Foods. He came to Target when the company was facing a different set of challenges. Cornell replaced former CEO Gregg Steinhafel, who stepped down nearly five months after Target disclosed a huge data breach in which hackers stole millions of customers' credit- and debit-card records. The theft badly damaged the chain's reputation and profits. Cornell reenergized sales by having his team rev up Target's store brands. It now has 40 private label brands in its portfolio. And even before the pandemic, Cornell spearheaded the company's mission to transform its stores into delivery hubs to cut down on costs and speed up deliveries. Target's 2017 acquisition of Shipt helped bolster the discounter's same-day, store-based fulfillment services. Cornell also focused on making its stores better tailored to the local community The coronavirus pandemic delivered outsized sales for Target as well as its peers as people stayed home and bought pajamas, furnishings and kitchen items. And it continued to see a surge in sales as shoppers emerged from their homes and went to stores. But the spending sprees eventually subsided. As inflation started to spike, Target reported a 52% drop in profits during its 2022 first quarter compared with a year earlier. Purchases of big TVs and appliances that Americans loaded up on during the pandemic faded, leaving the retailer with excess inventory that had to be sold off. In July 2023, as shoppers feeling pinched by inflation curtailed their spending, Target said its comparable sales declined for the first time in six years. Moreover, Target started losing its edge as an authority on style by focusing too much on home furnishings basics, and not enough trendy items, Fiddelke said. A customer backlash over the annual line of LGBTQ+ Pride merchandise Target stores carried that year further cut into sales. Although Walmart retreated from its diversity initiatives first, Target has been the focus of more concerted consumer boycotts. Organizers have said they viewed Target's action as a greater betrayal because the company previously had held itself out as a champion of inclusion.
Business Wire
31 minutes ago
- Business Wire
Enanta Pharmaceuticals Files Patent Infringement Suit Against Pfizer in the Unified Patent Court of the European Union
WATERTOWN, Mass.--(BUSINESS WIRE)-- Enanta Pharmaceuticals, Inc. (NASDAQ: ENTA), a clinical-stage biotechnology company dedicated to creating novel, small molecule drugs for viral infections and immunological diseases, announced today that it has filed suit in the Unified Patent Court (UPC) of the European Union against Pfizer Inc. and certain of its subsidiaries (action number 35071/2025), seeking a determination of liability for use and infringement of European Patent No. EP 4 051 265 (the '265 Patent) in the manufacture, use and sale of Pfizer's COVID-19 antiviral, Paxlovid™ (nirmatrelvir tablets; ritonavir tablets). This enforcement action targets Pfizer's activities in the 18 countries of the European Union that are presently participating in the UPC. The European Patent Office's recent grant of the '265 Patent to Enanta was published in the European Patent Bulletin today. The '265 Patent is based on Enanta's July 2020 patent application describing coronavirus protease inhibitors invented by Enanta scientists. The '265 Patent is the European counterpart of U.S. Patent No. 11,358,953 (the '953 Patent) involved in ongoing U.S. litigation between Enanta and Pfizer Inc. Under UPC procedures, a hearing on the infringement action is expected to occur within the UPC's published 12-month target, with the decision rendered within weeks thereafter. If the UPC determines there has been infringement, subsequent proceedings would be required to determine damages. All timelines remain subject to potential rights of appeal and other customary proceedings in European patent litigation. About Enanta Pharmaceuticals, Inc. Enanta is using its robust, chemistry-driven approach and drug discovery capabilities to become a leader in the discovery and development of small molecule drugs with an emphasis on indications in virology and immunology. Enanta's clinical programs are currently focused on respiratory syncytial virus (RSV) and its earlier-stage immunology pipeline aims to develop treatments for inflammatory diseases by targeting key drivers of the type 2 immune response, including KIT and STAT6 inhibition. Glecaprevir, a protease inhibitor discovered by Enanta, is part of one of the leading treatment regimens for curing hepatitis C virus (HCV) infection and is sold by AbbVie in numerous countries under the tradenames MAVYRET ® (U.S.) and MAVIRET ® (ex-U.S.) (glecaprevir/pibrentasvir). A portion of Enanta's royalties from HCV products developed under its collaboration with AbbVie contribute ongoing funding to Enanta's operations. Please visit for more information. Forward Looking Statements Disclaimer This press release contains forward-looking statements, including statements with respect to Enanta's filing in the UPC of a suit against Pfizer Inc. and certain of its subsidiaries seeking a determination of liability for use and infringement of Enanta's patent and Enanta's expectations with respect to any further action with respect to such proceedings. Statements that are not historical facts are based on management's current expectations, estimates, forecasts and projections about Enanta's business and the industry in which it operates and management's beliefs and assumptions. The statements contained in this release are not guarantees of future performance and involve certain risks, uncertainties and assumptions, which are difficult to predict. Therefore, actual outcomes and results may differ materially from what is expressed in such forward-looking statements. Important factors and risks that may affect actual results include: Enanta is competing to develop intellectual property in areas of small-molecule drug development that are highly competitive; issued patents, including those covering one or more of its product candidates, could be found invalid or unenforceable if challenged in court and could be costly to defend and be a distraction for Enanta's senior management and scientific personnel; intellectual property litigation may lead to unfavorable publicity that harms Enanta's reputation and causes the market price of its common stock to decline; and other risk factors described or referred to in 'Risk Factors' in Enanta's Form 10-K for the fiscal year ended September 30, 2024 and other periodic reports filed more recently with the Securities and Exchange Commission. Enanta cautions investors not to place undue reliance on the forward-looking statements contained in this release. These statements speak only as of the date of this release, and Enanta undertakes no obligation to update or revise these statements, except as may be required by law.
CNBC
32 minutes ago
- CNBC
Latham: We are starting to see demand rebound after the Covid hangover
Tony Latham, President-North America at Bacardi, joins Worldwide Exchange to discuss post-Covid recovery in spirits, Gen Z drinking habits, tequila growth, and why tariffs remain manageable.
